Bitget App
Trade smarter
Analyst: Bitcoin's monthly RSI is at 66, indicating a steady upward trend.

Analyst: Bitcoin's monthly RSI is at 66, indicating a steady upward trend.

CointimeCointime2025/11/02 15:48
By:Cointime

 well-known analyst PlanB said, "Bitcoin's monthly RSI is 66, with a steady upward trend."

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Arm's Low-Power Architectures Overcome AI Energy Constraints, Fuel 34% Growth in Revenue

- Arm Holdings reported $1.14B Q3 revenue, 34% YoY growth surpassing forecasts, driven by AI/data center demand. - Royalty revenue rose 21% to $620M while licensing revenue jumped 56% to $515M, reflecting strong IP adoption. - Strategic shift to develop full-chip solutions via Compute Sub Systems aims to compete with Nvidia/Amazon in AI hardware. - Parent company SoftBank explored Arm-Marvell merger to strengthen AI infrastructure, highlighting industry consolidation trends. - 20 "buy" ratings and $155 pri

Bitget-RWA2025/11/06 08:30
Arm's Low-Power Architectures Overcome AI Energy Constraints, Fuel 34% Growth in Revenue

Fed Faces a Choice: Boost Growth or Curb Mounting Debt?

- U.S. household debt hit $18.59 trillion in Q3 2025, driven by rising credit card, student loan, and home equity debt with delinquency rates at multi-year highs. - The Fed initiated rate cuts amid slowing job growth but faces a dilemma: easing economic strain risks inflating a consumer debt bubble while tightening worsens defaults. - Retailers, banks, and auto lenders face fallout as discretionary spending declines and loan defaults rise, while essential goods and debt collectors see increased demand. - P

Bitget-RWA2025/11/06 08:30
Fed Faces a Choice: Boost Growth or Curb Mounting Debt?

Antitrust Battle Ignites as Pfizer Obstructs Novo's $9 Billion Metsera Acquisition

- Novo Nordisk's $9B Metsera acquisition faces Pfizer lawsuits alleging antitrust violations and breach of contract under U.S. antitrust laws. - Pfizer claims the deal delays GLP-1 competition and binds Metsera to restrictive covenants, while Novo dismisses allegations as "baseless" and confident in antitrust compliance. - Novo cuts $8B annual costs, launches Wegovy pill, and partners with Costco/Walmart to counter 9% market share loss amid U.S. pricing pressures and patent expirations. - The obesity drug

Bitget-RWA2025/11/06 08:30